To hear about similar clinical trials, please enter your email below
Trial Title:
Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
NCT ID:
NCT05945524
Condition:
Multiple Myeloma
Conditions: Official terms:
Multiple Myeloma
Conditions: Keywords:
Teclistamab
Resistance
Immune Cell
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Other
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
Bone marrow sampling
Description:
Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)
Arm group label:
Analysis of bone marrow
Summary:
The aim of this study is to discover the immune and oncogenomic features that distinguish
patients who respond to teclistamab from patients who are primarily resistant. Moreover,
phenotypic and genotypic characteristics that occur with secondary resistance to
teclistamab will be analyzed.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- With multiple myeloma
- Who receive Teclistamab
- Consent form signed
Exclusion Criteria:
- Patient under legal protection
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
September 1, 2023
Completion date:
May 31, 2026
Lead sponsor:
Agency:
University Hospital, Toulouse
Agency class:
Other
Source:
University Hospital, Toulouse
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05945524
